Tresiba Pipeline and Next-Gen: What the Regulatory Record Shows and What Comes Next

FDA Approval History: A Two-Cycle Path to Market

Tresiba's route to FDA approval was not straightforward. Novo Nordisk submitted its original Biologics License Application (BLA) in 2012, but the FDA issued a complete response letter (CRL) in February 2013 requesting a dedicated cardiovascular outcomes trial (CVOT) before approval 1. That request came during a period when the FDA required cardiovascular safety data for all new diabetes therapies following the rosiglitazone controversy.

The EMA Moved First

The European Medicines Agency granted marketing authorization for Tresiba in January 2013, months before the FDA's CRL 2. European regulators accepted the existing phase 3 data showing noninferiority to insulin glargine without requiring a separate CVOT. This created a two-year gap where Tresiba was available in Europe and Japan but not in the United States.

The 2015 U.S. Approval

The FDA approved Tresiba on September 25, 2015, based on updated clinical data and Novo Nordisk's commitment to complete the ongoing DEVOTE trial 3. The approval covered both the 100 U/mL and 200 U/mL formulations for adults and pediatric patients aged 1 year and older with type 1 or type 2 diabetes. The 200 U/mL pen allows delivery of up to 160 units in a single injection, addressing a practical need for patients with high insulin requirements.

Label Evolution After Approval

The Tresiba prescribing information has been updated multiple times since 2015. A significant revision came in January 2019, when Novo Nordisk added results from the DEVOTE trial directly to the label, including the hypoglycemia benefit versus insulin glargine 4. That label update gave prescribers quantified safety data at the point of care, not just a generic cardiovascular noninferiority statement.

The DEVOTE Trial: Cardiovascular Safety and Hypoglycemia Data

The Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) enrolled 7,637 patients across 438 sites in 20 countries 5. It remains the defining dataset for Tresiba's safety profile.

Primary Endpoint: Cardiovascular Noninferiority

DEVOTE confirmed that insulin degludec was noninferior to insulin glargine U100 for major adverse cardiovascular events (MACE). The hazard ratio was 0.91 (95% CI: 0.78 to 1.06), meeting the prespecified noninferiority margin of 1.30 5. The trial was not powered to demonstrate superiority, and the upper bound of the confidence interval stayed well below 1.30.

Hypoglycemia: The Differentiating Finding

The more clinically actionable result was the 40% reduction in severe hypoglycemia with degludec compared to glargine U100 (rate ratio 0.60; P<0.001 for superiority) 5. Nocturnal severe hypoglycemia was reduced by 53% (rate ratio 0.47; P=0.002) 5. Dr. Steven Marso, the trial's lead investigator, stated: "The significant reduction in severe hypoglycemia with insulin degludec was observed across all prespecified subgroups, including patients with prior cardiovascular events" 5.

Post-Hoc Analyses and Real-World Confirmation

Subsequent analyses from the DEVOTE dataset explored the relationship between hypoglycemia and cardiovascular events. DEVOTE 3 found that severe hypoglycemia was associated with a significantly higher risk of subsequent MACE (HR 2.05; 95% CI 1.10 to 3.82) 6. This finding supported the clinical logic that reducing hypoglycemia may carry downstream cardiovascular benefit, although causation was not established.

Real-world evidence from the CONFIRM study (N=4,056) showed that patients switching to degludec from other basal insulins had lower HbA1c reductions and fewer hypoglycemic events compared to those switching to glargine U300, consistent with the DEVOTE signal 7.

Current Label and Safety Profile

The Tresiba prescribing information carries the standard insulin class warnings, but its label includes several distinguishing features compared to other basal insulins 4.

Dosing Flexibility

The label permits flexible daily dosing with a minimum of 8 hours between injections, a direct result of degludec's 42-plus-hour duration of action. This is unique among basal insulins. The FDA-approved labeling states: "If a dose is missed, administer the dose upon discovering the missed dose. Ensure that at least 8 hours elapse between consecutive Tresiba injections" 4.

Adverse Event Profile

The most common adverse reactions reported in clinical trials (incidence ≥5%) were hypoglycemia, nasopharyngitis, upper respiratory tract infection, and headache 4. Weight gain across phase 3 trials averaged approximately 2 to 3 kg over 52 weeks, comparable to insulin glargine.

FDA Adverse Event Reporting (FAERS) Signals

Post-marketing surveillance through the FDA's Sentinel system and FAERS database has not identified new safety signals beyond those described in the original label 8. Lipodystrophy and injection-site reactions remain the most frequently reported post-marketing concerns for the class. No pattern of increased cardiovascular events has emerged in over a decade of global post-marketing use.

Xultophy: The Combination Product

Novo Nordisk extended the degludec franchise with Xultophy (insulin degludec/liraglutide), approved by the FDA in November 2016 for type 2 diabetes 9. Each unit delivers 1 unit of degludec and 0.036 mg of liraglutide in a fixed-ratio combination.

Clinical Rationale

The DUAL program, comprising multiple phase 3 trials, demonstrated that the combination achieved greater HbA1c reduction than either component alone while offsetting the weight gain typically seen with insulin. In DUAL V (N=557), Xultophy reduced HbA1c by 1.8 percentage points versus 1.1 points with glargine U100 uptitration, with 3.2 kg less weight gain 10.

Regulatory and Market Position

Xultophy represents a regulatory approach that bundles GLP-1 receptor agonist benefits into a basal insulin format. Its label restricts use to patients already on basal insulin or liraglutide, or both. The product competes with Soliqua (insulin glargine/lixisenatide) in a small but growing fixed-ratio combination segment.

Patent Field and Biosimilar Pipeline

Tresiba's core U.S. Composition-of-matter patents have begun expiring or face challenge, opening the pathway for biosimilar development 11.

Patent Expiration Timeline

Novo Nordisk's primary U.S. Patent for insulin degludec (U.S. Patent No. 7,615,532) expired in 2023. Additional formulation and device patents extend protection into the mid-to-late 2020s, but these are narrower in scope. The company has historically used patent clusters to maintain market exclusivity for its insulin portfolio.

Biosimilar Development Activity

Several manufacturers have initiated biosimilar development programs for insulin degludec, though no biosimilar has yet received FDA approval as of May 2026. The regulatory pathway for insulin biosimilars was clarified when the FDA transitioned insulin products from drugs to biologics under the Biologics Price Competition and Innovation Act (BPCIA) in March 2020 12. That transition made the 351(k) abbreviated pathway available for insulin biosimilar applicants.

What Biosimilar Competition Could Mean for Patients

If insulin degludec biosimilars reach the U.S. Market, pricing dynamics could follow the pattern seen with insulin glargine biosimilars, where Semglee (glargine-yfgn) launched at roughly a 65% discount to Lantus list price 13. Access to ultra-long-acting basal insulin at reduced cost could affect formulary positioning and patient out-of-pocket expenses.

Next-Generation Basal Insulins: Beyond Tresiba

Novo Nordisk's own pipeline has moved beyond daily basal insulin. The most significant successor is insulin icodec (Awiqli), a once-weekly basal insulin that received its first regulatory approval from the EMA in 2024 14.

Insulin Icodec: Once-Weekly Dosing

The ONWARDS clinical trial program (ONWARDS 1 through 6) evaluated icodec across type 1 and type 2 diabetes populations. ONWARDS 1 (N=984) showed that once-weekly icodec was noninferior to once-daily glargine U100 for HbA1c reduction in insulin-naive type 2 diabetes patients, with an estimated treatment difference of -0.19 percentage points favoring icodec 15. The convenience of weekly dosing could reduce injection burden and improve adherence, particularly for patients who struggle with daily injections.

How Icodec Differs from Degludec

Icodec achieves its long half-life (approximately 196 hours) through strong albumin binding, distinct from degludec's multi-hexamer depot mechanism. The clinical tradeoff is that dose adjustments take longer to reach steady state, requiring careful titration algorithms. Hypoglycemia rates in the ONWARDS program were generally comparable to daily basal insulins, though the ONWARDS 3 trial in type 1 diabetes showed higher combined level 2 and level 3 hypoglycemia rates with icodec 16.

FDA Review Status for Icodec

Novo Nordisk submitted a BLA for insulin icodec to the FDA, with a decision expected in 2026. The FDA has requested additional data on hypoglycemia rates, particularly in type 1 diabetes, which could influence the approved indication scope 17. Whether icodec launches with a type 2-only indication or includes type 1 will shape its competitive positioning against Tresiba.

Other Pipeline Candidates

Beyond Novo Nordisk's own pipeline, Eli Lilly's basal insulin efsitora alfa (a once-weekly Fc-insulin fusion protein) has completed phase 3 trials with results comparable to degludec in the QWINT program 18. QWINT-2 (N=928) demonstrated noninferiority to degludec for HbA1c reduction in type 2 diabetes. A competitive once-weekly basal insulin market could accelerate the shift away from daily dosing.

Implications for Prescribers and Patients

Tresiba remains a well-characterized basal insulin with over a decade of global clinical and post-marketing data. Its regulatory record is notable for three reasons: the CVOT-driven approval pathway that produced the DEVOTE dataset, the quantified hypoglycemia advantage now embedded in the label, and the dosing flexibility claim that no other basal insulin carries.

Formulary Considerations Going Forward

As once-weekly insulins enter the market and degludec biosimilars approach filing, prescribers face a more complex decision matrix. The American Diabetes Association's 2024 Standards of Care recommend individualized basal insulin selection based on hypoglycemia risk, cost, and patient preference 19. The ADA notes: "For patients at high risk of hypoglycemia, longer-acting basal insulin analogs (U-300 glargine or degludec) are preferred over NPH insulin."

What to Watch

Two regulatory events will define the next chapter for this drug class: the FDA's decision on insulin icodec's approved indications, and the first biosimilar filing for insulin degludec. Both could occur within the next 12 to 18 months. For patients currently stable on Tresiba, the DEVOTE hypoglycemia data (40% severe hypoglycemia reduction vs. Glargine U100; rate ratio 0.60, P<0.001) remains the strongest evidence-based reason to continue therapy 5.